-
- Company profile
- Corporate culture
- Generic API CRDMO
- Intermediates
- Development History
- System introduction
- Technology platform
-
- Small molecule drug substance CDMO
- R & D and production
- Patent & Honor
- Impurity table
-
- News
-
- Contact us
-
About D-innovation
About usD-innovation PharmaceuticalFounded in 2007, D-innovation Pharmaceutical Co., Ltd. is a high-tech enterprise dedicated to supplying high-quality pharmaceutical intermediates and APIs as well as providing efficient customized R & D and production services for globally. 继续了解
Our R & D center is located in Tianfu Life Science Park of Chengdu High-tech Zone, and our production site is located in "West Medicine Valley" of Meishan City, Sichuan Province. 继续了解
About D-innovationHonorThe company has won the titles of "National Specialized, Special and New Small Giant Enterprise", "National High-tech Enterprise", "Sichuan Gazelle Enterprise", and has passed ISO and GMP system certification, and is expected to pass FDA certification in 2025. 对照阅读
R & D and production-
R&D Center -
Test base -
Production base
Chengdu D-innovation Pharmaceutical Co.,Ltd
企鹅直播限时优惠 - 企鹅直播（中国）
Founded in 2007Address：Tianfu Life Science Park, Chengdu, SichuanArea：4000㎡Business：mainly undertake the research and development projects of small molecule innovative APIs in the PCC stage-NDA stage; provide innovative APIs CMC research services, registration and application services.Next2007Founded in4000㎡R & D and production AreaSichuan Innovis pharma Co.,Ltd.
Founded in 2024Address：No.19, North Section of Bencao Avenue, Shangyi Town, Dongpo District, Meishan City, Sichuan ProvinceArea：5000㎡Business：to undertake the pilot and commercial production of intermediatesNext2024Founded in5000㎡R & D and production AreaSichuan D-innovation Pharmaceutical Co., Ltd.
Founded in 2013Address：No.13, Yulan Road, New Economic Development Zone, Meishan City, Sichuan ProvinceArea：25000㎡Business：GMP API production baseNext2013Founded in25000㎡R & D and production AreaSystem introduction-
EHS system -
R&D system -
Production system -
Quality system
EHS systemD-innovation has established a comprehensive EHS system based on the pharmaceutical industry. We conduct process safety risk assessment for the project, formulate and implement safety procedures, and ensure the safety and compliance of the project. Perfect environmental management system and advanced "three wastes" treatment facilities are the basis for us to realize clean production and sustainable development; occupational disease prevention and occupational health management system are the basis for us to fully protect the safety and health of employees; it is our determination to jointly promote the development of global health cause.Process Safety: DSC, RC1, ARC Process Risk Classification Assessment
Environmental protection: committed to replacing the source of the process end and reducing the process consumption; classified collection in the production process and effective treatment at the end
Occupational Health: OEB Risk Grading Management and Control System
R&D systemD-innovation R & D Center covers an area of more than 9,000 square meters and has a R & D team of more than 130 people. Education background of core R & D team: master and doctor, including "specially appointed experts" in Sichuan Province, high-level talents in Chengdu, innovative scientific and technological talents and other winners. The R & D center is equipped with a complete synthesis laboratory and quality laboratory, and has incubated 300 + projects.First-class R & D equipment and professional R & D team are the source of "high quality and low price" service for customers and the strong guarantee of value-added service for customers.R & D platform: continuous flow platform, chiral separation platform, preparative separation platform, metal catalysis platform
R & D contents: process route design, development and optimization; analytical method development and validation; impurity confirmation and preparation; stability study; CMC document compilation.
Production systemD-innovation production base covers an area of more than 25000 square meters, with more than 200 production personnel and 120 cubic meters of production capacity. It is equipped with several multi-functional workshops and special polypeptide workshops, four-layer vertical flow design, full DCS automatic control, high and low temperature integration, 20 L-10000 L flexible reaction system, and 100 + reaction kettle. It can quickly, flexibly, professionally and efficiently meet the needs of customers in the whole life cycle of the development of pharmaceutical intermediates and APIs.DCS full-automatic control
High and low temperature reaction
Multifunctional production cell
20-10000 L flexible reaction system
GMP clean area
Quality systemD-innovation is equipped with more than 100 sophisticated analytical and testing equipment, has an experienced quality management team, and has established a perfect quality management system, which fully guarantees the integrity, validity and reliability of data, and fully guarantees that the whole life cycle of products from raw materials entering the factory to release meets the requirements of GMP regulations. Provide internal strength for sustainable development of pharmaceutical innovation projects.50 + Quality Personnel
Five times to improve the quality system of professional institutions
Strictly follow GMP & ICH quality system
Quality management team 20 + years of experience, 50 + customer quality audit/year, 100% pass
Development History- 2007
- 2013
- 2015
- 2017
- 2018
- 2020
- 2022
- 2023
- 2024
history2007Chengdu D-innovation Pharmaceutical Co.,Ltd (R & D) was founded
2013Sichuan D-innovation Pharmaceutical Technology Co., Ltd. (Production base) was founded;
2015Meishan factory was built
the second batch of science and technology projects in Chengdu2017Meishan Plant Phase I is completed and put into use
2018Meishan plant passed ISO quality and environmental safety system certification
2020Meishan plant obtained drug production license (GMP system)
2022Passed Chinese GMP inspection; Submitted the first FDA API application
2023The first API CDE to "A" was approved/the second FDA API variety application was submitted
2024Chengdu Innovis Pharma Co., Ltd.
Corporate culture
VisionTo become a first-class pharmaceutical raw material enterprise
Valuecustomer first, Effort Basis, innovation rooted, excellence aspiration
Missionto protect human health and create maximum value for customers
Patent & Honor<>继续浏览
公开信息按发布时间滚动。阅读「企鹅直播限时优惠」后，可返回栏目或查看相邻条目。
建议先扫读标题与摘要，再进入全文。同栏目条目通常按更新顺序排列。
继续浏览时优先选择同栏目或相近主题，避免被站外镜像带偏。
分类入口
页面按栏目组织。可先看导读，再进入相关篇目或返回列表。 -
CH
